Andrea R. Filippi

Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 231 publications

Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol.

Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol.

Journal: Biomedicines

Published: May 25, 2026

Radiochemotherapy for salivary gland adenoid cystic carcinoma: survival assessment through a retrospective study exploiting real-world data extracted from data warehouse.

Radiochemotherapy for salivary gland adenoid cystic carcinoma: survival assessment through a retrospective study exploiting real-world data extracted from data warehouse.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 16, 2025

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

Journal: JNCI cancer spectrum

Published: November 18, 2025

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Journal: Clinical and translational radiation oncology

Published: October 21, 2025

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 09, 2025

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

Journal: ESMO open

Published: September 11, 2025

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 05, 2025

Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 18, 2025

Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy.

Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy.

Journal: The Lancet. Oncology

Published: August 13, 2025

Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 09, 2025

Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.

Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.

Journal: Clinical lung cancer

Published: May 22, 2025

Showing 1-12 of 231

Last Updated: 09/26/2026